Publications directory

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm

The web Directory of Information Materials for People Affected by Cancer is regularly updated and currently has details of over 1,900 booklets, leaflets, books and audiovisual materials for people affected by cancer. Most have been published in the last five years but we have included some older ones that are still useful.

Results: 27

Cover image of 'Acute promyelocytic leukaemia (APL). A guide for patients'

Acute promyelocytic leukaemia (APL). A guide for patients (January 2020)

Leukaemia Care

Acute promyelocytic leukaemia (APL) is a rare sub-type of acute myeloid leukaemia (AML). This booklet explains it what it is, and describes the symptoms, diagnosis, and treatment options. It also covers practical issues of living with APL and how to talk to your haematologist, family and friends.

Cover image of 'Acute promyelocytic leukaemia (APL)'

Acute promyelocytic leukaemia (APL) (November 2019)

Blood Cancer UK

Acute promyelocytic leukaemia (APL) is a form of cancer affecting the stem cells that produce myeloid blood cells in the bone marrow. This booklet explains who gets APL and what causes it, and describes the signs and symptoms, the diagnosis, the two types of APL, the treatment options (including the long-term effects of treatment) and the prognosis.

Cover image of 'ATRA and anthracycline based therapy for acute myeloid leukaemia (AML). A guide for patients'

ATRA and anthracycline based therapy for acute myeloid leukaemia (AML). A guide for patients (March 2018)

Leukaemia Care

All-trans retinoic acid (ATRA), known as Tretinoin (Vesanoid®) is the acid form of vitamin A, which is used with chemotherapy for induction of remission in patients with confirmed acute promyelocytic leukaemia (APL), a subtype of acute myeloid leukaemia. This booklet describes the use of ATRA along with the chemotherapy drugs idarubicin and mitoxantrone.

Cover image of 'FLAG-Ida for acute myeloid leukaemia (AML). A guide for patients'

FLAG-Ida for acute myeloid leukaemia (AML). A guide for patients (January 2020)

Leukaemia Care

FLAG-Ida is a combination chemotherapy regimen used in the treatment of acute myeloid leukaemia (AML). It consists of fludarabine, high dose cytarabine (Ara-C0), idarubicin and granulocyte-colony stimulating factor (G-CSF). This booklet explains the drugs, who may be eligible to receive this treatment, how FLAG-Ida is given, and the possible side-effects. Includes a glossary and details of further support and information.

Cover image of 'Acute myelomonocytic leukaemia (AMML). A guide for patients'

Acute myelomonocytic leukaemia (AMML). A guide for patients (October 2019)

Leukaemia Care

Acute myelomonocytic leukaemia (AMML) is a rare type of acute myeloid leukaemia (AML). This booklet explains it what it is, and describes the symptoms, diagnosis, prognosis, and treatment options. It also covers issues such as telling your family, managing your emotions, and survivorship. Includes a glossary and sources of support.

Cover image of 'Acute megakaryoblastic leukaemia (AMKL). A guide for patients'

Acute megakaryoblastic leukaemia (AMKL). A guide for patients (March 2019)

Leukaemia Care

Acute megakaryoblastic leukaemia (AMKL) is a rare subtype of acute myeloid leukaemia (AML). It is more common in children than in adults. In children with Down syndrome, AMKL is the most common type of AML. This booklet explains what it is, the signs and symptoms, how it is diagnosed and the treatment options. Includes a glossary and details of support.

Cover image of 'B-cell acute lymphoblastic leukaemia (ALL). A guide for patients'

B-cell acute lymphoblastic leukaemia (ALL). A guide for patients (May 2019)

Leukaemia Care

This booklet explains what B-cell acute lymphoblastic leukaemia is, and describes the causes, who it affects, the symptoms and side-effects and treatment options. It also covers issues such as day-to-day life with B-cell acute lymphoblastic leukaemia, managing your emotions, telling family and friends, survivorship, palliative care, and end-of-life care.

Cover image of 'Azacitidine for acute myeloid leukaemia (AML). A guide for patients'

Azacitidine for acute myeloid leukaemia (AML). A guide for patients (June 2019)

Leukaemia Care

Azacitidine is a chemotherapy drug used for the treatment of adult patients with acute myeloid leukaemia, high risk myelodysplastic syndrome or chronic myelomonocytic leukaemia who are not eligible for stem cell transplant. This booklet is for patients, family or friends of the patient, or a carer who like to know more about this drug. It describes what azacitidine is, how it is given, and the possible side-effects. It also has details of useful information and support.

Cover image of 'CAR-T therapy. A guide for patients'

CAR-T therapy. A guide for patients (October 2019)

Leukaemia Care

Chimeric antigen receptor T-cell (CAR-T) therapy is a new type of cancer treatment that may be used to treat B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma (DLBCL). This booklet explains how CAR-T therapy works and who may currently receive it, and describes the possible side-effects. It also discusses the likely future for CAR-T therapy and the clinical trials currently taking place in the UK. It includes a glossary of terms and details of further information and support.

Cover image of 'Childhood acute lymphoblastic leukaemia (ALL). A guide for parents'

Childhood acute lymphoblastic leukaemia (ALL). A guide for parents (March 2019)

Leukaemia Care

Being told that your child has acute lymphoblastic leukaemia (ALL) can be a shock and very upsetting, particularly when you may never have heard of the disease. This booklet describes childhood ALL, what causes it, who it affects, how it affects your child’s body, what symptoms to expect and likely treatments. It also covers everyday life and childhood ALL and talking about childhood ALL. Includes a glossary of terms and details of useful contacts and further support.

Sorry, no publications found.
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm